PT - JOURNAL ARTICLE AU - EUN JI LEE AU - SOO JIN PARK AU - JEESUN LEE AU - JAEHEE MUN AU - HAERIN PAIK AU - AERAN SEOL AU - JUNHWAN KIM AU - GA WON YIM AU - SEUNG-HYUK SHIM AU - HEE SEUNG KIM AU - SUK-JOON CHANG AU - on behalf of the KoRIA Trial Group TI - The Clinical Desire for Pressurized Intraperitoneal Aerosol Chemotherapy in South Korea: An Electronic Survey-based Study AID - 10.21873/anticanres.15494 DP - 2022 Jan 01 TA - Anticancer Research PG - 363--371 VI - 42 IP - 1 4099 - http://ar.iiarjournals.org/content/42/1/363.short 4100 - http://ar.iiarjournals.org/content/42/1/363.full SO - Anticancer Res2022 Jan 01; 42 AB - Background/Aim: To evaluate the clinical desire for pressurized intraperitoneal aerosol chemotherapy (PIPAC) in South Korea. Patients and Methods: We performed an online survey on surgical oncologists between November and December 2019 using a questionnaire consisting of 20 questions. Results: A total of 164 respondents answered the questionnaire. Among those specialized in ovarian cancer, pseudomyxoma peritonei, and malignant mesothelioma 41.7-50% preferred PIPAC for the curative treatment of primary diseases, whereas 32.7-33.3% majoring in colorectal and hepatobiliary cancers chose it for the palliative treatment of recurrent diseases. Furthermore, 66.7-95.2% considered PIPAC appropriate for the cancers they specialized in, and 76-78.7% expected a treatment response of more than 50% and considered grade 1 or 2 complications acceptable. Most respondents answered the reasonable costs to purchase and implement PIPAC once at between 1,000,000-5,000,000 South Korean Won (KRW). Conclusion: Most Korean surgical oncologists expected relatively high tumor response rates with minor toxicities through the repeated implementation of PIPAC.